gold standard for assessing the methylation status of MGMT, there are limitations to this process. It requires an invasive procedure where there is still the possibility of incomplete biopsy sampling due to a spatially heterogeneous glioblastoma. Sufficient samples may be difficult to obtain if the tumor is inaccessible to the surgeon. Therefore, it would be helpful in predicting treatment response and prognosis if it were possible to noninvasively determine MGMT methylation status with preoperative imaging. A few studies have described distinctive radiological features of glioblastoma with MGMT methylation using conventional MRI and diffusion-weighted or diffusion tensor imaging (DTI). 5, 14, 15 However, there are some discrepancies between the reports; some investigators have reported that the apparent diffusion coefficient (ADC) value is lower in the MGMT methylated group, 15 whereas others have reported that the ADC ratio is significantly higher in the MGMT methylated group.
14 While some studies have reported an enhancement pattern or tumor margin characteristic that appears to be associated with MGMT methylation status, others have not found such an association. 5, 6, 9, 14 Dynamic contrast-enhanced (DCE) MRI using a contrast agent is an emerging MRI technique based on kinetic modeling of microvascular permeability that enables quantification of blood-brain barrier (BBB) breakdown. 18 Several studies have shown efficacy of permeability parameters from DCE-MRI in glioma grading. 12, 17 However, no study has evaluated the association between permeability parameters and MGMT methylation status in glioblastoma. Therefore, the aim of this study was to identify imaging biomarkers for MGMT methylation using quantitative parameters from DTI and DCE-MRI in addition to conventional imaging features.
Methods
The institutional review board approved this retrospective study and did not require patient approval or informed consent for the review of patient images. However, we did obtain informed consent for MGMT promoter gene evaluation at the time of surgery.
Patients
We retrospectively studied 49 patients between October 2011 and January 2013 from the neurooncology database at our institution on the basis of the following criteria: 1) a histopathological diagnosis of glioblastoma based on the WHO grading system and 2) a record of preoperative MRI performed with DTI and DCE-MRI. We excluded 6 patients due to the following conditions: inadequate MRI (n = 3), failure to obtain informed consent for MGMT promoter gene evaluation (n = 2), or stereotactic biopsy (n = 1). Accordingly, 43 patients were enrolled (25 men and 18 women; mean age 58 ± 14.5 years). The characteristics of the 43 patients are shown in Table 1 .
The mean interval between preoperative MRI and surgery was 5.8 ± 4.3 days. Of the 43 patients, 18 underwent gross-total resection, 21 underwent subtotal resection, and 4 underwent partial resection. All pathological specimens were examined by an experienced neuropathologist (K.S.H.), and the MGMT methylation status was assessed with methylation-specific polymerase chain reaction.
Image Acquisition
Preoperative MR images were obtained using a 3.0-T system (Achieva, Philips) and an 8-channel SENSE head coil. The preoperative evaluation MRI protocol included the following conventional sequences: pre-and postcontrast T1-weighted imaging (TR 2000 msec, TE 10 msec, FOV 240 mm, slice thickness 5 mm, and matrix 256 × 256), T2-weighted imaging (TR 3000 msec, TE 80 msec, FOV 240 mm, slice thickness 5 mm, and matrix 256 × 256), and fluid-attenuated inversion recovery (TR 10,000 msec, TE 125 msec, FOV 240 mm, slice thickness 5 mm, and matrix 256 × 256).
For DCE-MRI, precontrast 3D T1-weighted images were obtained with the following parameters: TR 6.3 msec, TE 3.1 msec, FOV 240 mm, matrix 192 × 192 mm, slice thickness 3 mm, and flip angle 5°. After the precontrast scan, 60 DCE T1-wighted images were obtained with the same MR parameters except for an increased flip angle of 15°. After acquisition of the fifth image volume, gadolinium-based contrast (0.1 ml/kg gadobutrol, Gadovist, Bayer Schering Pharma) was injected at a rate of 3 ml/sec. The acquisition time for DCE-MRI was 378 seconds.
Diffusion tensor images were obtained by applying 6 different directions of orthogonal diffusion gradients and b values of 1000 seconds/mm 2 and 0 seconds/mm 2 (TR 8400 msec, TE 77 msec, FOV 240 mm, slice thickness 2 mm, and matrix 128 × 128).
Qualitative Imaging Analysis
Two neuroradiologists (S.S.A. and N.Y.S.) who were blinded to the patients' molecular and clinical data reviewed the conventional MR images on a standard picture archiving and communication system. All tumors were assessed for the following imaging features: enhancing tumor margin (well or poorly defined); enhancement patterns (ring, nodular, or mixed enhancement); presence of edema, cysts, necrosis, and nonenhancing tumor; and heterogeneity of the signal intensity on the T2-weighted images. Briefly, necrosis was defined as regions of pe- 
Quantitative Imaging Analysis
An experienced neuroradiologist (S.S.A.) who was blinded to molecular and clinical data performed postprocessing. Permeability maps from DCE-MRI, including volume transfer constant (Ktrans), rate transfer coefficient (Kep), and volume fraction of extravascular extracellular space (Ve) maps, were generated by off-line Pride tools, based on the pharmacokinetic model of Tofts and Kermode, 18 provided by Philips Medical Systems. Postprocessing comprised motion correction of pixels from dynamic images, T1 mapping using different flip angles (5° and 15°), registration of pixels on a T1 map, vascular input function estimation, and pharmacokinetic modeling. All of these processes were automatically performed by Pride tools except for the drawing of regions of interest (ROIs) for vascular input function. The ROIs for the vascular input function were drawn from the vertical part of the superior sagittal sinus on the middle section of the scanned volume. For volume-based analysis, ROIs were drawn to contain all enhancing components of the tumor in each section of the Ktrans, Kep, and Ve maps, referring to the underlay information from the postcontrast imaging and excluding nonenhancing areas (Fig. 1) . The mean values of these parameters were used for analysis.
All DICOM data for DTI were transferred to a commercial software package (Nordic ICE, Nordic Imaging Lab). The parametric maps for the ADC and fractional anisotropy (FA) were coregistered with postcontrast T1-weighted images. As with the permeability maps, ROIs were drawn to contain all enhancing components of the tumor in each section of the ADC and FA maps, referring to the underlay information from the postcontrast imaging and excluding nonenhancing areas (Fig. 1) . The mean values of these parameters were used for analysis. We evaluated intraobserver agreements by comparing initial measurements with repeated measurements by a same investigator using the same technique.
Statistical Analysis
Imaging features were correlated with MGMT methylation status using chi-square tests or Fisher's exact tests. Interobserver agreement for each imaging feature was calculated using the kappa statistic. A kappa value of 0.81-1.0 indicated excellent agreement between the 2 observers; 0.61-0.80 indicated good agreement, 0.41-0.6 indicated moderate agreement, 0.21-0.4 indicated fair agreement, and 0-0.2 indicated only slight agreement. 8 Intraobserver agreements for quantitative imaging parameters were evaluated with the intraclass correlation coefficient.
Based on normality testing, Mann-Whitney U-tests with Bonferroni correction were used to evaluate the relationships between MGMT methylation status and quantitative imaging parameters. We performed receiver operating characteristic curve analysis to find the optimal cutoff value for the presence of MGMT methylation.
All statistical analyses were performed using statistical software (SAS version 9.2, SAS Institute Inc.; and MedCalc version 9.3.6.0, MedCalc Software); p values < 0.05 were considered significant.
Results
Among 43 patients, 16 (37.2%) cases of glioblastoma had confirmed MGMT methylation, comparable to rates of MGMT methylation in other studies.
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Qualitative Imaging Analysis and MGMT Methylation Status
Interobserver agreement for imaging features was good to excellent, with kappa values of 0.622 for tumor margin, 0.630 for enhancement pattern, 0.946 for edema, 0.839 for cysts, 0.78 for necrosis, 0.952 for nonenhancing tumor regions, and 0.788 for T2 signal intensity. Table 2 summarizes the imaging features that were qualitatively assessed on conventional imaging between the 2 glioblastoma groups. The MGMT methylation status was not significantly associated with any imaging features.
Quantitative Imaging Analysis and MGMT Methylation Status
Intraobserver agreements for quantitative imaging , p = 0.168); Ve, ADC, and FA were not different between the 2 groups (Table 3 ). According to the receiver operating characteristic curve analysis, the optimal cutoff value for the presence of MGMT methylation was a Ktrans value > 0.086 min -1 with an area under the curve of 0.756, a sensitivity of 56.3%, and a specificity of 85.2% (Fig. 4) .
Discussion
Our results indicate that Ktrans can be used to predict MGMT methylation status. Glioblastoma with MGMT methylation shows a higher Ktrans value than glioblastoma without MGMT methylation. Several studies have demonstrated that permeability measurements with DCE-MRI may be helpful in discriminating the malignant potential of glioma by showing that the Ktrans of low-grade gliomas is lower than that of high-grade gliomas. 3, 12, 17 High-grade tumors with a higher proportion of immature vessels from neoangiogenesis have increased endothelial permeability, which facilitates the transfer of contrast agents from plasma into the extracellular space. Therefore, one might expect that glioblastomas with MGMT methylation, which have been well documented to have a better prognosis, would demonstrate less aggressive features and hence a lower level of endothelial permeability than glioblastoma without MGMT methylation. Although we cannot adequately explain the reason, one explanation for these results could be that an increased Ktrans in glioblastomas with MGMT methylation signifies easier penetration of temozolomide and thus results in increased therapeutic success. One study found longer survival in cases with higher Ktrans when only high-grade gliomas were considered. 13 The authors postulated that the positive relationship between Ktrans and survival is due to improved drug delivery to tumor tissues. Likewise, increased Ktrans in glioblastomas with MGMT methylation might represent improved passage of temozolomide via leaky blood vessels, resulting in a better prognosis. Pseudoprogression, a transient radiological increase in contrast enhancement after concurrent radiochemotherapy that is consequent to the breakdown of the BBB, has been reported to be more frequent in glioblastomas with MGMT methylation; the overall survival of patients with pseudoprogression was significantly higher than in those without pseudoprogression.
1 Our results support the high prevalence of pseudoprogression in glioblastoma with MGMT methylation because the favorable treatment response might have contributed to the increased endothelial permeability to chemotherapeutic agents in this tumor. Although temozolomide can cross the BBB, increased permeability is thought to impact intratumoral concentrations of this drug. 20 In our study, the ADC and FA values from DTI were not significantly different between the MGMT methylated and unmethylated groups. This result is discordant with findings from previous studies. Pope 14 However, the latter study included both WHO Grade III and IV tumors with a small number of patients in each group. One explanation for such variable results could be that ADC and FA values can be affected by multiple factors. For example, ADC is lowered by high cellularity but is increased by edema and necrosis, which are common in glioblastoma. Moreover, FA reflecting destruction of the white matter due to tumor infiltration shows potentially dramatic regional and anatomy-specific variations. In addition, these studies used variable quantitative imaging analysis methods. We used the mean ADC value from ROIs corresponding to the entirety of the enhancing tumor, while Pope at al. used mean values for the lower peak of the ADC fitted with a binormal distribution from ROIs corresponding to the entirety of enhancing tumor, and Moon et al. used minimum ADC values and ADC ratios from 6 ROIs. Further investigations are warranted to address the potential role of DTI in predicting MGMT methylation status. Previously, nodular and mixed nodular enhancement patterns and ill-defined enhancing tumor margins have been reported to be associated with MGMT methylation. 5, 6, 14 However, none of our conventional imaging features were significantly associated with MGMT methylation status, with p values ranging from 0.092 to 1. In accordance with our results, Gupta et al. 9 also reported that there were no significant differences in imaging features between the groups after qualitative assessment of conventional MRI.
In practice, most suspicious tumors are biopsied, and imaging prediction of MGMT methylation may have limited clinical benefit. However, a recent study reported that MGMT expression and promoter methylation might vary throughout a single glioblastoma, and consequently, results might depend on the site of surgical sampling. 4 Therefore, imaging biomarkers could be the only tool capable of resolving this intratumoral heterogeneity and might serve as a surrogate for histopathology when pathology sampling is suboptimal. Furthermore, it could be of value if future preoperative treatment regimens are developed.
There are several issues with our study that need to be addressed. First, 21 patients underwent subtotal resection. However, a majority of the enhancing portions were removed, and we excluded 1 patient who underwent stereotactic biopsy, which assumes the histological specimen is representative of the entire tumor without a significant sampling error. Second, we analyzed quantitative parameters from areas with tumor enhancement only because this would be more reproducible than including areas of nonenhancing tumor, which can be ill defined or obscured by edema. Third, we did not measure interobserver variability for quantitative analysis. However, we obtained mean values from ROIs containing all enhancing components of the tumor in each section rather than ROIs from representative sections, which might have mitigated some of the measurement error in the spatially heterogeneous glioblastoma.
Conclusions
Transfer constant (Ktrans) of DCE-MRI may serve as a potential imaging biomarker to predict MGMT methylation status preoperatively in glioblastoma. However, further investigation with a larger cohort is necessary. Disclosure Fig. 4 . Receiver operating characteristic curve analysis for the prediction of MGMT promoter methylation status. The optimal cutoff value for the presence of MGMT methylation was a Ktrans > 0.086 min -1 with an area under the curve of 0.756.
